Reduced drug efficacy from target mutation, efflux-pump upregulation, metabolic bypass, or sanctuary sites. Antimicrobial (MRSA, XDR-TB), antiviral (HIV), anticancer (BCR-ABL T315I). Drives combination therapy.
Reduced drug efficacy from target mutation, efflux-pump upregulation, metabolic bypass, or sanctuary sites. Antimicrobial (MRSA, XDR-TB), antiviral (HIV), anticancer (BCR-ABL T315I). Drives combination therapy.